Bipolar Disorder Trial, Recruiting NCT06507787 Sponsor: Alcediag Condition: Bipolar Disorder
Back to Bipolar Disorder

Bipolar Disorder Trial, Recruiting

NCT06507787
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged between 18 and 65 years, of any gender, who are experiencing a moderate to severe major depressive episode (based on standard psychiatric criteria and a specific symptom score of 19 or above on a rating scale called the MADRS)
  • People who have health insurance coverage
  • People who have given written consent and agreed to follow the study procedures through to completion
  • People for whom there is some uncertainty about whether they may have bipolar disorder, and/or who have one or more of the following: more than 3 depressive episodes in their lifetime; psychotic symptoms; a family member with bipolar disorder; a first depressive episode before the age of 25; unusual or mixed symptoms during depressive episodes; a history of addiction; a personal history of suicide attempts; a lack of response to antidepressants; or depression that began within 6 months of giving birth

Who may not be able to join:

  • People whose depression is connected to a diagnosis of schizophrenia or autism spectrum disorder
  • People who already have a confirmed diagnosis of bipolar disorder
  • People who are already taking a medication called a mood stabiliser
  • People with serious physical health conditions that could interfere with follow-up care or that are linked to treatments that may carry a risk of triggering a manic episode
  • People with a neurodegenerative disease (a condition where the nervous system progressively deteriorates, such as Parkinson's or Alzheimer's disease)
  • People who are pregnant

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: +33788970700

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Alcediag
Registry
ClinicalTrials.gov
Start date
3 February 2025
Est. completion
1 May 2026

Where this trial is recruiting

🇫🇷 France

Primary endpoints

Improvement in depressive symptoms between inclusion and 15-16 weeks visit.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov